Tuesday, June 24, 2014 3:08:09 PM
There are no peer-reviewed publications (at leat of which I am aware) showing data that confirm the company's assertions that toxicity to animals is low or non-existant, or that effectiveness has been demonstrated for 'Cides in animals against any particular virus.
More specifically - and in this particular circumstance - I assert that the (technically correct) fact that there are no peer-reviewed publications showing these data being used against NNVC is beyond irrelevant. It is to be expected that most, if not all of the data have not been subjected to peer review as there is significant IP and 'trade secret' information that needs to be protected.
Fact also is - that even accepting the (I aruge false) premise that NNVC's insiders might have good reason to (potentially, IF they are unethical scammers) guild the lilly on the effectiveness of their 'Cides in animal models to keep their company afloat and enrich themselves,...... Outsiders like Dr. Harris have absolutly no reasonable reason to play along and sully their own reputations.
Fact is - the IND application will require all of this information to be disclosed prior to entering into Phase I trials. Specifically why we are still 'Pre-IND' here rather than 'IND'. We need to more detailed TOX data to cross that threshold. That's the only way to really quiet all the noise and misinformation that gets tossed about.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM